Contact
searchSearch
HMP Global
Login
Videos

Considering the Impact of Bone Marrow Diseases on the Progression of Myeloid-Related Neoplasms

Pinkal Desai, MD
10/14/2025

 

Pinkal Desai MD, MPH, Weill Cornell Medical College, New York, New York, shares the importance of identifying and treating bone marrow diseases in efforts to reduce patients’ risk of developing myeloid-related neoplasms at the 2025 Lymphoma, Leukemia & Myeloma (LL&M) Congress in New York, New York. 

 

Source:

Desai P. CHIP, CCUS, and Other 4-letter Marrow Diseases. Presented at Lymphoma, Leukemia & Myeloma Congress; October 14-17, 2025. New York, NY.

© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of LL&M, Oncology Learning Network or HMP Global, their employees, and affiliates.

Related Content

Gabriela Hobbs, MD
Videos
Novel Therapies and Strategies for Treating Patients With Myeloproliferative Neoplasms
02/08/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Gabriela Hobbs, MD, discusses innovative therapies and strategies for treating patients with myeloproliferative neoplasms.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Gabriela Hobbs, MD, discusses innovative therapies and strategies for treating patients with myeloproliferative neoplasms.
At the 2025 Lymphoma, Leukemia &...
02/08/2025
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
Abdulraheem Yacoub, MD
Conference Coverage
Developments in Utilizing Interferons for the Treatment of Myeloproliferative Neoplasms
09/04/2024
Abdulraheem Yacoub, MD
Abdulraheem Yacoub, MD, shares expert insight into the use of interferons for the treatment of patients with myelofibrosis, essential thrombocythemia, and polycythemia vera.
Abdulraheem Yacoub, MD, shares expert insight into the use of interferons for the treatment of patients with myelofibrosis, essential thrombocythemia, and polycythemia vera.
Abdulraheem Yacoub, MD, shares...
09/04/2024
Oncology
News
Optimizing Hydroxyurea Management Among Patients With Polycythemia Vera
08/09/2023
Amber Denham
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.
More optimal hydroxyurea...
08/09/2023
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use